Clean Science and Technology: Green chemistry, process innovation key levers
Over the years, Clean Science and Technology has optimised the use of conventional raw materials, improved yields, and reduced effluent discharges, which have consequently helped in cost competitiveness
Clean Science and Technology Ltd - 543318 - Announcement under Regulation 30 (LODR)-Newspaper Publication
Pursuant to Regulation 30 read with Schedule III and Regulation 47 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we enclose copies of the newspaper advertisement published in Financial Express and Loksatta on 8th February, 2022, regarding the Unaudited Financial Results (Stand-alone and Consolidated) for the quarter and nine months ended 31st December, 2021.
Earnings Call for Q3FY22 of Clean Science & Technology
Conference Call with Clean Science & Technology Management and Analysts on Q3FY22 Performance and Outlook. Listen to the full earnings transcript. Q3FY22 Quarterly Result Announced for Clean Science & Technology Ltd.
Specialty Chemicals firm Clean Science and Technology declares Q3FY22 result: Mixed quarter: Recorded highest ever revenue and PAT in Q3 FY2022 . Total revenues increased by 18% and 44% on QoQ and YoY basis respectively Despite end product price hike, gross margins impacted as raw material price increase was steeper during Q3. Other key factors impacting margins are coal prices and moderation in product mix with pharma segment share significantly higher in Q3 compared to Q2 Focus on sustainability Company has been awarded the “Greenco Silver” rating by GreenCo - Green Company Rating System. Clean Science and Technology Limited is the first specialty chemical company in the country to be given the “Greenco” certification This rating is a clear validation of our company’s emphasis on clean, green and sustainable practices and processes Product launch and capex Commissioned plants for manufacturing PBQ (Para benzoquinone), BHA and TBHQ. PBQ is an import substitute with Clean Science being the only company in India to manufacture PBQ Cash capex of ~INR 110 crore cumulatively during 9M FY2022, all funded from internal accruals Performance chemicals - Increased realizations across all products. Strong volume offtake for BHA during Q3 FY22 compared to Q3 FY21 Pharma chemicals – Increased volume offtake across products, improved realizations for DCC during Q3 FY22 compared to Q3 FY21 FMCG chemicals – Increased volume offtake and improved realizations for all key products in Q3 FY22 compared to Q3 FY21 Result PDF Clean Science and Technology Ltd - 543318 - Announcement under Regulation 30 (LODR)-Investor Presentation
In accordance with Regulation 30 read with Schedule III of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, Financial Results presentation for quarter ended 31st December, 2021 is enclosed. Clean Science and Technology Ltd - 543318 - Announcement under Regulation 30 (LODR)-Change in Directorate
The Board of Directors of the Company, at their meeting held today viz. Monday, 7th February, 2022, approved seeking consent of shareholders by way of Postal Ballot on the following resolutions 1.To approve continuation of employment of Mr. Ashok Ramnarayan Boob, Managing Director of the Company, consequent to him attaining the age of 70 years w.e.f. 2nd March, 2022. 2.To approve re-appointment of Mr. Ashok Ramnarayan Boob, as Managing Director of the Company for further term of 5 years w.e.f. from 28th July, 2022. Clean Science and Technology Ltd - 543318 - Financial Results For The Quarter Ended 31.12.2021
Financial Results for the quarter ended 31.12.2021 Clean Science and Technology Ltd - 543318 - Board Meeting Outcome for Outcome Of Board Meeting
The Board of Directors, at their meeting held today viz. Monday, 7th February, 2022, considered the following: - 1. Approved Unaudited Standalone and Consolidated Financial Results for the quarter and nine months ended 31st December, 2021. 2. Approved seeking consent of shareholders by way of Postal Ballot on the following: a) To consider and approve the modifications in CSTL Employee Stock Option Scheme, 2021 b) To ratify the CSTL Employee Stock Option Scheme, 2021 c) To approve continuation of employment of Mr. Ashok R. Boob, MD consequent to him attaining the age of 70 years w.e.f. 2nd March, 2022. d) To approve re-appointment of Mr. Ashok R. Boob, as MD for further term of 5 years w.e.f. from 28th July, 2022 e) To approve payment of aggregate annual remuneration in excess of 5% of net profits of the Company in a year which includes Fixed Remuneration and 4% Performance Bonus collectively to all the Executive Directors who are promoters till the expiry of their respective terms. Clean Science and Technology Ltd - 543318 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
In terms of the referred Regulation 30 read with Schedule III - Part A to SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we would like to inform you that a conference call for analysts and investors has been scheduled on Monday, 7th February, 2022 at 05:30 p.m. (IST) to discuss on the financial results for the quarter ended 31st December, 2021.